MFMaria Fasshauer

Maria Fasshauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Fasshauer has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Wiederkehrende, unklare Bauchschmerzen in Rahmen eines Hereditären Angioödems

    by Maria Fasshauer

    Wiederkehrende, unklare Bauchschmerzen können Ausdruck eines Hereditären Angioödems (HAE) sein. Abdominelle Schwellungsattacken treten bei nahezu allen HAE-Betroffenen auf und sind bei etwa der Hälfte das einzige Symptom. Typisch sind krampfartige, progrediente Bauchschmerzen, die (unbehandelt) 2–5 Tage andauern, häufig begleitet von Blähungen, Übelkeit, Erbrechen oder Durchfall. HAE sollte auch dann als Differenzialdiagnose erwogen werden, wenn periphere Hautschwellungen fehlen oder nicht zeitgleich auftreten. Aufgrund der eher unspezifischen Symptomatik kommt es häufig zu einer Verzögerung der Diagnosestellung, was unnötige invasive Diagnostik oder operative Eingriffe zur Folge haben kann. Eine frühzeitige Diagnose ermöglicht den Einsatz wirksamer spezifischer Therapien und senkt Morbidität und Mortalität deutlich [1] [2] [3] [4] [5]. Article published online: 20 March 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Inborn Errors of Immunity und rheumatisch-entzündliche Autoimmunität

    by Maria Fasshauer

    Zusammenfassung: Rheumatische Symptome wie Arthritis, Vaskulitis und Autoinflammation können (Erst)-Manifestation von IEI sein und sind meist assoziiert mit pathologischen Infektionen und weiteren autoimmun-autoinflammatorischen Komplikationen. Das Erkennen eines IEI hat entscheidende therapeutische Implikationen und ermöglicht teilweise gezielte Ansätze, die die zugrunde liegende Immunpathologie adressieren. Eine frühe Diagnosestellung soll systemische Komplikationen und Organschäden vermeiden und die Lebensqualität der Betroffenen verbessern. Gen-Varianten, die mit seltenen monogenen IEI assoziiert sind, findet man aber auch in Verbindung mit polygenen rheumatischen Erkrankungen. Einblicke in Kandidatengene und ein besseres Verständnis genetischer, molekularer sowie immunologischer Mechanismen sowie genetischer Netzwerke und epigenetischer und weiterer Einflussfaktoren auf diese Mechanismen und Immuneffektoren können helfen, zielgerichtete Therapien auch für polygene entzündlich-rheumatische Krankheitsbilder zu finden.

  • Open Access

    A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents

    by Maria Fasshauer, Gesine Schuermann, Norbert Gebert, Horst von Bernuth, Monika Bullinger, Sigune Goldacker, Renate Krueger, Petra Manzey, Stefanie Messner, Ellen D Renner, et al.

    Aim: To assess a patient empowerment program (PEP) for children/adolescents with primary immunodeficiency (PID) on IgG replacement therapy regarding quality of life (QoL) in patients and proxy. Patients & methods: Health-related QoL was assessed using KIDSCREEN-27 and DISABKIDS-37 before and 6 months after PID-PEP kids in 19 children/adolescents and their parents. Results: The following three dimensions of the KIDSCREEN-27 significantly increased in children/adolescents after PID-PEP kids as compared with baseline: Psychological Well-Being, Parents & Autonomy and School Environment. Total DISABKIDS-37 index, as well as 5 of the 6 DISABKIDS-37 dimensions, significantly increased, in other words, Independence, Emotion, Social Inclusion, Social Exclusion and Physical. Evaluation of proxy instruments showed comparable results. Conclusion: PID-PEP kids significantly improved QoL in patients with PID.


  • Open Access

    Hereditary angioedema (HAE) in children and adolescents: New treatment options

    by Maria Fasshauer, Bettina Wedi

    Modern management of hereditary angioedema (HAE) due to reduced C1 inhibitor (C1-INH) function or concentration (HAE-C1-INH) focuses on individualized therapeutic strategies to address the specific needs of children and adolescents as well as the severity of the disease. Psychosocial factors such as the burden of disease and therapy on quality of life and participation play an important role. New medications have already significantly improved the prognosis and health related quality of life in HAE patients, but not all of these therapies have yet been approved for children. Further treatment options that inhibit bradykinin effects are currently being investigated. They target or the bradykinin B2 receptor. Modern research focuses on oral options or long-acting parenteral therapy approaches to further optimize care and, in particular, the needs of children. There are also initial developments in the field of gene therapy, which could represent a causal treatment option for HAE in the future.


  • Sozialleistungen für Kinder und Jugendliche mit rheumatischen Erkrankungen

    by Maria Fasshauer, Franziska Dunst

    Patient:innen und deren Familien mit einer neu diagnostizierten chronischen Erkrankung sind zunächst mit vielen Problemen konfrontiert. In Deutschland ist die medizinische Behandlung von Kindern und Jugendlichen mit chronischen Erkrankungen und/oder Behinderungen im Sozialgesetzbuch (SGB) V festgeschrieben [1]. Der Artikel soll einen Überblick zu potenziellen Fragen bezüglich Sozialleistungen oder sonstigen Unterstützungsangeboten darstellen und grob auf verschiedene Hilfen eingehen. In der Praxis kann eine gezielte Sozialberatung Informationen und Wegweiser bei Themen wie Selbsthilfe, Teilhabe, Erziehung, Bildung, Freizeit, Schule/Arbeit, Prävention, Rehabilitation und Pflege bieten. Wichtig ist es, die Familien auf dieses Angebot hinzuweisen. Patients with a recently diagnosed chronic disease and their families are confronted with a variety of different problems. In Germany medical treatment of people with chronic conditions and disabilities is regulated by law (SGB V). This article provides an overview about different social benefits and support services. In daily practitioners’ routine topics like participation, support groups, documented status of severe disability, financial benefits, care, work/school, and rehabilitation need to be addressed. Therefore, an educated specialized advisor gives assistance to affected patients and their families concerning their rights and support services. Article published online: 16 October 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases

    by Maria Fasshauer, Michael Borte, Michaela Bitzenhofer, Christine Pausch, David Pittrow, Michelle Park, André Gladiator, Peter Jandus

    Introduction The CORE study aimed to provide a detailed understanding of real-world immune globulin subcutaneous (human) 20% solution (Ig20Gly) utilization in patients with primary immunodeficiency diseases (PIDs) in Germany and Switzerland. Methods Patients with PIDs receiving a stable dose of any subcutaneous immunoglobulin for ≥ 3 months before enrollment were eligible for this multicenter (n = 5), phase 4, non-interventional, prospective, longitudinal cohort study. Besides baseline demographics and clinical characteristics, Ig20Gly utilization and safety data, and patient-reported outcomes (Life Quality Index/Treatment Satisfaction Questionnaire for Medication) were collected at baseline, 6 and 12 months. Statistical analysis was descriptive. Results Overall, 36 patients provided data at baseline [69.4% female; mean age: 41.6 years (7–78 years)]. Totals of 23 and 26 patients attended 6- and 12-month visits, respectively; 16 attended all three visits. One patient withdrew consent before 6-month follow-up. Median maximum infusion rates of Ig20Gly at baseline, 6 months, and 12 months were 26.7, 24.5, and 40.0 mL/h, respectively (10–60 mL/h). Infusion and dosing parameters remained consistent across time points: patients used a median of two infusion sites, primarily the abdomen, and all patients used an infusion pump; all but one infused at home and most self-administered Ig20Gly (80.8–83.3%) at once-weekly intervals (69.2–73.9%). During follow-up, 10 adverse events were reported: none were rated serious, while 2 were considered probably related to Ig20Gly. Total patient-reported outcome scores remained high throughout the study. Conclusion The CORE study provides real-world evidence of the flexibility, feasibility, safety, and tolerability of Ig20Gly infusions, at mostly weekly intervals, over 1 year in patients with PIDs. Trial Registration German Clinical Trials Register, DRKS00014562. Registered April 9, 2018, https://drks.de/search/en/trial/DRKS00014562


  • Open Access

    Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases

    by Ulrich Baumann, Maria Fasshauer, Christine Pausch, Helmut Wittkowski, Corinna Hermann, David Pittrow, Michael Borte

    Aim: While facilitated subcutaneous immunoglobulin (fSCIG) has been evaluated in pediatric patients with primary immunodeficiency diseases in clinical trials, real-world data are lacking. Materials...


  • Open Access

    Hereditary angioedema in children and adolescents – A consensus update on therapeutic strategies for German‐speaking countries

    by V Wahn, W Aberer, E Aygören-Pürsün, K Bork, W Eberl, M Faßhauer, R Krüger, M Magerl, I Martinez-Saguer, P Späth, et al.

    Background/Methods: At a consensus meeting in August 2018, pediatricians and dermatologists from German‐speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE‐C1‐INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE‐C1‐INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life‐threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This article provides recommendations for developing appropriate treatment strategies in the management of HAE‐C1‐INH in pediatric patients in German‐speaking countries. An overview of available drugs in this age‐group is provided, together with their approval status, and study results obtained in adults and pediatric patients.Results/Conclusion: Currently, plasma‐derived C1 inhibitor concentrates have the broadest approval status and are considered the best available option for on‐demand treatment of HAE‐C1‐INH attacks and for short‐ and long‐term prophylaxis across all pediatric age‐groups in German‐speaking countries. For on‐demand treatment of children aged 2 years and older, recombinant C1‐INH and bradykinin‐receptor antagonist icatibant are alternatives. For long‐term prophylaxis in adolescents, the parenteral kallikrein inhibitor lanadelumab has recently been approved and can be recommended due to proven efficacy and safety.